Robert Half heads into its third-quarter report with a split personality. Its core staffing business appears to have finally turned the corner, while its Protiviti consulting arm is still working through a regulatory slowdown in financial services that management now expects to last through year-end. The stock has lagged badly since the last report, so the question is simple. Is the staffing recovery strong enough to carry the whole company until Protiviti stabilizes?

Wall Street expects earnings of $0.47 a share on revenue of $1.36 billion when the company reports after the close on October 22. Both figures sit right at the midpoint of management's guidance of $0.43 to $0.53 a share and $1.31 billion to $1.41 billion in revenue. Analysts are not asking for heroics. Revenue is expected to be essentially flat from a year ago, up just 0.4%. Earnings are projected to rise about 9% from $0.43, which reflects cost cuts and a better staffing mix more than any real top-line momentum. The comparison with last quarter's $0.26 is misleading, because that result absorbed a severance charge tied to Protiviti restructuring.

The staffing side carries the burden of proof. Last quarter, permanent placement revenue grew 2.5% from a year earlier, its first gain after a long run of declines that hit roughly 11% at the worst point. Contract staffing ended the quarter down only 2%, and early July was down just 1%. Management said this was the third straight quarter of sequential improvement and argued the bottom is in. Guidance implies Talent Solutions grows about 3% year over year at the midpoint. Confirming that thesis requires contract revenue to turn clearly positive and perm growth to build on, not just repeat, last quarter's gain. Technology, the strongest contract practice, is the area to check for early signs of acceleration. One soft spot is pricing. Contract bill-rate growth slowed for several straight quarters, down to 2.3%, as wage inflation cooled. If bill rates keep slipping, the recovery has to come almost entirely from volume.

Protiviti is where the story could crack. Management cut its outlook for the segment to a decline of 4% to 8%, well below earlier expectations, and its adjusted gross margin fell to 18.5% from about 22% a year ago. International work also turned negative as public-sector projects in Germany and Belgium wound down. The company has two answers. First, it raised its annualized cost-savings target from $30 million to $45 million. Second, it says non-financial-services work, especially technology consulting, which just had a record quarter, is filling the gap. A stable or improving margin, plus evidence that the pipeline growth management cited is turning into revenue, would back up its claim that the drag is temporary. A result at the weak end of the range, or another margin decline, would suggest the problem is deeper than a regulatory lull.

The market has been skeptical. Shares fell 6.6% since the last report while the S&P 500 gained 4.5%, an 11-point gap. That happened even as sentiment readings improved to modestly bullish from a weaker starting point. At $34.39, the stock sits much closer to its post-earnings low of $32.88 than its high of $46.70, though it remains above its 200-day moving average. That combination of better operating signals and a beaten-down share price gives the company room to surprise, but only if the numbers back up the improved tone.

The real test is whether the staffing turnaround keeps building. If contract revenue moves into growth and perm keeps improving, investors can likely tolerate a few more quarters of Protiviti weakness. The fourth-quarter outlook matters as much as the third-quarter results, since management has already flagged a lost billing day that will cut about $20 million of revenue. If staffing stalls instead, the bottom-is-in argument loses its foundation, and Protiviti's problems will look much harder to ignore.